Form 4: Corcept Therapeutics Insider Trades Revealed

Sean Maduck, President of Corcept Endocrinology, engaged in significant stock transactions, including acquisitions and sales, on July 1, 2026, under a Rule 10b5-1 plan.

Summary

• Sean Maduck, President of Corcept Endocrinology, reported a series of stock transactions on July 1, 2026.
• These transactions included the acquisition of 25,000 shares of common stock at $8.27 per share, likely related to stock options.
• Maduck also disposed of a total of 24,999 shares of common stock across three separate sales at weighted average prices ranging from $87.3349 to $89.3094.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
• Following these transactions, Maduck directly beneficially owns 23,731 shares and indirectly beneficially owns a substantial number of shares through various trusts and LLCs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While significant sales occurred, they were executed under a pre-defined plan, mitigating concerns of opportunistic selling. The acquisition of shares at a lower price is a positive indicator.

Positives

• The acquisition of 25,000 shares at a lower price ($8.27) suggests potential for future gains if the stock price increases.
• The transactions were executed under a pre-established Rule 10b5-1 plan, indicating a structured and potentially less market-sensitive approach to trading.
• Maduck continues to hold a significant number of shares indirectly, demonstrating ongoing commitment to the company.

Negatives

• A significant number of shares (24,999) were sold, which could be interpreted as a lack of confidence by a key executive, despite being part of a plan.
• The sales occurred at prices significantly higher than the acquisition price, indicating the executive is realizing substantial gains.

Risks

• The sale of a large number of shares by a key executive, even under a 10b5-1 plan, could be perceived negatively by the market.
• Future stock performance is subject to the inherent risks of the pharmaceutical industry and Corcept Therapeutics' specific drug development pipeline.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The power of attorney under which this form was signed is on file with the Commission.
• President, Corcept Endocrinology

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, are common in the biopharmaceutical sector as executives diversify holdings or manage personal finances. However, the volume and timing relative to company news can influence market perception.

Stakeholder Impact

• Shareholders may interpret the significant sales by a key executive with mixed feelings, potentially leading to short-term stock price fluctuations.
• Employees may view the executive's stock sales as a sign of confidence in the company's future, or as a personal financial decision.

Next Steps

• Continued monitoring of insider trading activity for any further significant transactions.
• Analysis of Corcept Therapeutics' future financial reports and clinical trial updates.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Sean Maduck, Stock Options, Rule 10b5-1, Beneficial Ownership, Stock Sales, Executive Compensation